<i>In vivo</i> Therapeutic Synergism of Anti–Epidermal Growth Factor Receptor and Anti-HER2 Monoclonal Antibodies against Pancreatic CarcinomasChristel Larbouret(Inserm), D. Azria(Inserm)Clinical Cancer ResearchJune 1, 200710.1158/1078-0432.ccr-06-2302Cited by 84SaveCiteExport RISWatch citationsRelated PapersCombined cetuximab and trastuzumab are superior to gemcitabine in the treatment of human pancreatic carcinoma xenografts|Annals of Oncology|2009|49HER3 as biomarker and therapeutic target in pancreatic cancer: new insights in pertuzumab therapy in preclinical models|Oncotarget|2014|44